Journal of Clinical & Experimental Cardiology
ISSN: 2155-9880
OPEN ACCESS Freely available online
Short Communication

Inherited Polymorphism Association with Cardiac Functional Variability

Nicolas Beaumont*

Department of Cardiovascular Genetics, École de Médecine de Lyon, Lyon, France

DESCRIPTION

Inherited genetic polymorphisms represent common variations in Deoxyribonucleic Acid (DNA) sequence that occur within populations and may influence biological traits without directly causing disease on their own. In cardiology, such polymorphisms are increasingly recognized as contributors to variability in cardiac structure, electrical activity, and functional performance among individuals exposed to similar environmental and clinical conditions. Cardiac functional variability refers to differences in heart rate behavior, contractile efficiency, conduction properties, and hemodynamic responses observed across patients, even in the absence of overt structural abnormalities [1].

The cardiovascular system is highly sensitive to genetic regulation, particularly in pathways involving ion channels, adrenergic signaling, myocardial contractile proteins, and neurohormonal control. Small variations in genes encoding these components can alter protein expression or function, resulting in measurable differences in cardiac performance [2]. These effects may remain subtle in healthy individuals but become clinically relevant under physiological stress, pharmacological intervention, or disease conditions. One of the most studied areas involves polymorphisms affecting cardiac ion channels. Variations in genes responsible for sodium, potassium, and calcium channel function can influence the duration of cardiac action potentials and the stability of electrical conduction. These differences may manifest as variability in resting heart rate, susceptibility to arrhythmias, or altered responses to stress-induced tachycardia. Even within normal populations, such polymorphisms contribute to differences in electrocardiographic patterns and rhythm stability [3].

Adrenergic receptor gene polymorphisms also play an important role in cardiac functional variability. Variants in beta-adrenergic receptor genes can modify the sensitivity of the heart to sympathetic stimulation. Individuals with certain polymorphic forms may exhibit enhanced or reduced heart rate responses during exercise, emotional stress, or pharmacological stimulation. This variability can influence exercise tolerance, blood pressure response, and susceptibility to conditions involving excessive sympathetic activation [4,5]. Contractile protein gene polymorphisms influence myocardial mechanical performance. Variations in genes encoding structural proteins such as myosin heavy chain, actin, and troponin complexes can subtly affect myocardial contraction efficiency. While many of these polymorphisms do not produce overt cardiomyopathy, they may contribute to inter-individual differences in stroke volume, ejection fraction, and ventricular compliance under physiological load conditions [6].

Neurohormonal regulation of cardiovascular function is also subject to genetic variation. Polymorphisms in genes involved in the renin-angiotensin-aldosterone system can alter vascular tone regulation, fluid balance, and cardiac remodeling responses. Individuals with specific variants may demonstrate differences in blood pressure regulation, ventricular hypertrophy tendency, and response to antihypertensive therapy. These effects contribute to variability in clinical outcomes among patients with similar environmental risk profiles [7]. Cardiac functional variability associated with inherited polymorphisms is particularly evident during stress conditions such as exercise testing or pharmacological challenge. Under baseline conditions, compensatory mechanisms may mask subtle genetic influences. However, when cardiovascular demand increases, differences in heart rate response, contractile reserve, and vascular adaptation become more pronounced. This reveals the functional significance of genetic variability in dynamic physiological states [8].

Pharmacogenomic interactions further highlight the clinical relevance of inherited polymorphisms. Variations in genes affecting drug metabolism or receptor sensitivity can influence response to cardiovascular medications [9]. For example, beta-blocker efficacy, antiarrhythmic drug response, and vasodilator sensitivity may differ significantly among individuals due to underlying genetic differences. This contributes to variability in treatment outcomes even when standardized therapeutic protocols are applied. From a clinical perspective, recognition of genetic contributions to cardiac functional variability has implications for risk assessment and personalized treatment strategies. Although routine genetic screening is not universally implemented in all cardiovascular evaluations, targeted testing is

Correspondence to: Nicolas Beaumont, Department of Cardiovascular Genetics, École de Médecine de Lyon, Lyon, France, E-mail: nicolas.beaumont@researchmail-global.org

Received: 30-Jan-2026, Manuscript No. JCEC-26-42419; **Editor assigned:** 02-Feb-2026, PreQC No. JCEC-26-42419 (PQ); **Reviewed:** 16-Feb-2026, QC No. JCEC-26-42419; **Revised:** 23-Feb-2026, Manuscript No. JCEC-26-42419 (R); **Published:** 02-Mar-2026, DOI: 10.35248/2155-9880.26.17.999

Citation: Beaumont N (2026). Inherited Polymorphism Association with Cardiac Functional Variability. J Clin Exp Cardiolog. 17:999.

increasingly used in patients with unexplained arrhythmias, cardiomyopathies, or atypical drug responses. Identification of relevant polymorphisms can support more precise therapeutic decision-making and improve prediction of disease progression in selected cases.

Population-based studies have demonstrated that genetic variability accounts for a measurable portion of differences in cardiovascular parameters such as heart rate variability, blood pressure response, and ventricular performance. However, these genetic effects interact strongly with environmental and lifestyle factors, including diet, physical activity, stress exposure, and comorbid conditions [10]. The resulting phenotype is therefore a combined expression of inherited predisposition and external influences. Despite advances in genetic research, interpretation of polymorphism-related cardiac variability remains complex. Many polymorphisms exert small individual effects, and their clinical significance often depends on interactions with other genetic variants and environmental factors. Ongoing research in cardiovascular genomics aims to better characterize these interactions and improve understanding of how genetic diversity influences cardiac function across populations.

CONCLUSION

Inherited polymorphisms contribute significantly to variability in cardiac functional behavior through their effects on ion channel activity, adrenergic signaling, myocardial contractility, and neurohormonal regulation. While often subtle in isolation, these genetic differences become clinically meaningful under stress conditions and in the presence of cardiovascular disease. Recognition of genetic contributions to cardiac variability supports a more individualized approach to cardiovascular assessment and treatment, with the potential to improve risk stratification and therapeutic precision in clinical cardiology practice.

REFERENCES

1. Young H, Benton D. We should be using nonlinear indices when relating heart-rate dynamics to cognition and mood. Sci Rep. 2015;5:16619.
2. Fatisson J, Oswald V, Lalonde F. Influence diagram of physiological and environmental factors affecting heart rate variability: An extended literature overview. Heart Int. 2016;11(1):e32-e40.
3. Ernst G. Heart-rate variability-more than heart beats?. Front Pub Health. 2017;5:240.
4. Riese H, Muñoz LM, Hartman CA, Ding X, Su S, Oldehinkel AJ, et al. Identifying genetic variants for heart rate variability in the acetylcholine pathway. PLoS One. 2014;9(11):e112476.
5. Draghici AE, Taylor JA. The physiological basis and measurement of heart rate variability in humans. J Physiol Anthropol. 2016;35(1):22.
6. Parati G, Mancia G, Di Rienzo M, Castiglioni P. Point: Cardiovascular variability is/is not an index of autonomic control of circulation. J Appl Physiol. 2006;101(2):676-678.
7. Servant D, Logier R, Mouster Y, Goudemand M. Heart rate variability. Applications in psychiatry. Encephale. 2009;35(5): 423-428.
8. McCraty R, Shaffer F. Heart rate variability: New perspectives on physiological mechanisms, assessment of self-regulatory capacity, and health risk. Glob Adv Health Med. 2015;4(1):46-61.
9. Dampney RA. Central neural control of the cardiovascular system: Current perspectives. Adv Physiol Educ. 2016;40(3):283-296.
10. Ma P, Li T, Ji F, Wang H, Pang J. Effect of GABA on blood pressure and blood dynamics of anesthetic rats. Int J Clin Exp Med. 2015;8(8):14296-14302.